CRSP Director Ali Behbahani Acquires 75 Shares via Distribution

What Happened
Ali Behbahani, a director of CRISPR Therapeutics AG (CRSP), acquired a total of 75 common shares on August 6, 2025 through a pro rata distribution from NEA Partners 15. The transaction consisted of 60 shares delivered directly to the reporting person and 15 shares delivered to the Ali Behbahani Revocable Trust; both were reported at $0.00 per share (total reported value $0). This was a distribution (not an open-market purchase or sale).

Key Details

• Transaction date: August 6, 2025; Filing date (Form 4): September 21, 2026 — the Form 4 was filed late.
• Reported transactions: 60 shares @ $0.00 (acquired) and 15 shares @ $0.00 (acquired); combined = 75 shares, reported value $0.
• Footnotes: NEA Partners 15 made a pro rata distribution for no consideration (F1,F2). The 15 shares were received by the Ali Behbahani Revocable Trust; Ali Behbahani is trustee and disclaims beneficial ownership of trust-held shares where he has no pecuniary interest (F3).
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• This was a non‑cash distribution (code J on the Form 4). Distributions or gifts generally do not reflect an insider’s market sentiment the way purchases or open‑market sales might.
• The late filing delays public disclosure; ordinarily Form 4s must be filed promptly (typically within two business days of the transaction), so the late filing reduces the timeliness of this disclosure for investors.